secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001323885-23-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q4 revenue $88M (+20.2% YoY); FY2022 revenue $330.4M (+20.4%); guides FY2023 rev $380-387M
--------------------------------------------------------------------------------

- Q4 2022 revenue $88.0M, up 20.2% YoY; U.S. revenue $73.9M (+20.7%), international $14.1M (+17.8%).
- Q4 gross margin 74.0% (vs 75.1% prior year); loss from operations improved to $4.1M from $12.5M.
- Q4 adjusted EBITDA turned positive at $6.0M (vs -$2.1M); adjusted loss per share $0.09 (vs $0.30).
- FY2022 revenue $330.4M (+20.4%); U.S. $277.2M (+21.0%), international $53.2M (+17.7%).
- FY2023 guidance: revenue $380-387M (15-17% growth); adjusted EBITDA break-even; adjusted loss per share $1.14-$1.19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000012/0001323885-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000012/atrc-20230221.htm
  HTML page:      https://secwatch.observer/filing/0001323885-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer